Angimet

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angimet

Quick Facts

Property Description
Active Ingredient Metoprolol (Succinate or Tartrate)
Form Oral tablet (often extended-release)
Pharmacological Class Cardioselective Beta-Blocker
Common Use Cardiovascular support
Origin Synthetic compound

What Type of Medication is Angimet (Metoprolol)?

Angimet is a synthetic prescription medication containing the active ingredient Metoprolol, primarily used for cardiovascular support. It is classified as a cardioselective beta-blocker (adrenergic beta-antagonist), placing it in the broader category of antihypertensive agents.

The medication's core substance, Metoprolol, is administered as a salt, typically Metoprolol Succinate or Metoprolol Tartrate. Metoprolol is a recognized beta-blocker used throughout clinical practice. As a selective beta-blocker, Metoprolol preferentially blocks the beta-1 receptors mainly found in the heart, focusing the therapeutic effect on cardiac function and helping to promote a more controlled circulatory state. Notable brands containing this substance include Lopressor and Toprol-XL.


Understanding Angimet’s Form and General Purpose

Angimet is administered via the oral route and is commonly available as an extended-release tablet, often indicated by an "XL" designation. This extended-release formulation utilizes specialized excipients to control the drug's dissolution rate. The goal is a steady delivery of the medication over a full day, a delivery method designed to maintain continuous therapeutic levels. This sustained release helps ensure round-the-clock cardiovascular support and is a key feature distinguishing it from immediate-release products.

The medication’s fundamental purpose is to reduce cardiac strain. By shielding the heart's receptors from excessive stimulation by stress hormones like adrenaline, Angimet works to slow the heart rate and decrease the force of contraction. This collective action minimizes the workload on the heart, providing a typical use scenario of stabilizing cardiac rhythms in patients requiring long-term heart support.

Regulatory References

  1. Metoprolol: MedlinePlus Drug Information

What side effects are possible with Angimet?

Possible Side Effects and Safety Information

The official safety profile for Angimet (Metoprolol) is structured by classifying documented adverse reactions based on their frequency and the physiological systems affected, as outlined by government health authorities. Reactions are officially grouped into System-Organ Classes (SOC) such as Cardiac Disorders, Nervous System Disorders, and Gastrointestinal Disorders.

Frequency-Classified Adverse Reactions

Adverse reactions that are Common (occurring in 1% to 10% of patients) generally include tiredness (fatigue), dizziness, bradycardia (slow heart rate), hypotension, and gastrointestinal effects such as nausea or diarrhea. Uncommon and Rare adverse reactions are also documented, encompassing events like confusion, insomnia, visual disturbances, and sexual dysfunction.

Serious Adverse Reactions and Safety Restrictions

Regulatory documents highlight serious adverse reactions that are of clinical importance. These include severe bradycardia, worsening of heart failure, and the possibility of cardiogenic shock. The medicine is formally restricted (contraindicated) in patients with conditions such as decompensated heart failure, sick sinus syndrome (without a pacemaker), and severe peripheral arterial circulatory disorders.

Population- and Time-Related Safety

Specific safety considerations exist for certain populations. For instance, Metoprolol may mask the signs of hypoglycemia in patients with diabetes and requires caution in those with hepatic impairment. A critical safety note is related to duration: abrupt cessation of Angimet may be associated with an exacerbation of underlying heart conditions, such as worsening angina or increasing the risk of myocardial infarction, as documented in official labeling.

Overdose and Emergency Response

The official regulatory documentation for Angimet (Metoprolol) overdose emphasizes severe, potentially life-threatening physiological disturbances and mandates immediate medical intervention. Overdosage may be characterized by profound cardiovascular compromise, including severe bradycardia, critical hypotension, and atrioventricular block. These symptoms can escalate to worsening cardiac failure and the development of cardiogenic shock or death.

Respiratory distress, specifically bronchospasm and hypoxia, along with central nervous system effects such as impairment of consciousness or coma, are also documented clinical manifestations.

The labeling explicitly states that no specific antidote is known for Metoprolol overdose. Therefore, management must be symptomatic and based on modern methods of intensive care and monitoring. Upon recognition of acute intoxication, immediate medical attention is required.

Official management procedures described in regulatory texts include gastric lavage for drug elimination and the administration of specific supportive agents such as Glucagon and intravenous vasopressors to manage cardiovascular instability. Patients with recent myocardial infarction or established heart failure are cited in official labeling as being particularly susceptible to significant hemodynamic instability during an overdose event.

Therapeutic Uses of Angimet

What Angimet treats: main uses and benefits

Angimet contains the active substance trimetazidine, a metabolic agent designed to support cardiac function. It is primarily used in the long-term management of specific heart conditions where blood flow to the heart muscle is restricted.

Main Therapeutic Uses

The medication is indicated for the symptomatic treatment of adult patients with stable angina pectoris. Angina is characterized by chest pain or discomfort that occurs when the heart muscle does not receive enough oxygen-rich blood.

Angimet is typically utilized as an add-on therapy. This means it is prescribed for patients whose symptoms are not sufficiently controlled by first-line angina treatments, or for those who cannot tolerate other types of anti-anginal medications.

Mechanism and Benefits

Unlike many other heart medications that work by altering heart rate or dilating blood vessels, Angimet works at the cellular level.

  • Metabolic Support: It helps protect the energy metabolism of heart cells during periods of low oxygen (hypoxia or ischemia).
  • Preservation of Function: By maintaining cellular energy levels, it helps the heart muscle continue to function more efficiently under stress.
  • Reduction of Symptoms: The primary goal of treatment is to reduce the frequency and severity of angina attacks.
  • Improved Exercise Tolerance: Patients may find an increased ability to perform physical activities with a lower risk of experiencing chest pain.

By stabilizing the metabolic environment within the cardiac cells, Angimet helps limit the functional damage caused by insufficient blood supply, contributing to a better quality of life for individuals with chronic stable angina.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Angimet (Trimetazidine) is restricted to use by adult patients only. Regulatory documents specify clear groups who should not use this medicine or must use it with caution, based strictly on official governmental labeling.

Populations Strictly Prohibited (Contraindicated)

  • Patients with hypersensitivity to Trimetazidine or any of the inactive ingredients.
  • Patients diagnosed with Parkinson disease, parkinsonian symptoms (such as tremor or rigid posture), restless leg syndrome, or other related movement disorders.
  • Patients with severe renal impairment (creatinine clearance less than 30 mL/min). Treatment must be discontinued definitively if movement disorders occur.

Restricted Use and Special Considerations

  • Pediatric Population: Use is not recommended for children and adolescents under 18 years of age as safety and efficacy have not been established.
  • Kidney Function: Patients with moderate renal impairment (creatinine clearance 30-60 mL/min) require caution and a dose reduction.
  • Elderly Patients: Individuals over 75 years old require caution and a dose adjustment is generally recommended.
  • Pregnancy and Lactation: Use is preferably avoided during pregnancy as a precautionary measure, and it should not be used during breast-feeding as a risk to the infant cannot be excluded.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Angimet (Metoprolol) outlines specific interactions that can affect exposure and cardiac function, which strictly follow pharmacokinetic and pharmacodynamic mechanisms described in the product labels.

Pharmacokinetic Interactions

Co-administration with strong inhibitors of the CYP2D6 enzyme—including medicines such as quinidine, fluoxetine, and paroxetine—is documented to increase metoprolol plasma concentration several-fold. This increase in exposure can diminish Angimet’s beta1-cardioselectivity. The regulatory label also notes that individuals identified as CYP2D6 Poor Metabolizers naturally exhibit several-fold higher plasma concentrations.

Pharmacodynamic Interactions and Restrictions

Combining Angimet with agents that slow heart rate or depress conduction results in additive pharmacodynamic effects. This includes Digitalis Glycosides and certain Calcium Channel Blockers (Verapamil, Diltiazem), leading to a documented increased risk of marked bradycardia and reduced cardiac conduction. Co-administration with Catecholamine-Depleting Drugs (e.g., Reserpine) may similarly result in additive effects, causing hypotension or bradycardia.

Regarding administration timing, the regulatory document specifies that if co-therapy with Clonidine is being discontinued, Angimet must be gradually withdrawn several days prior to the cessation of Clonidine to avoid exacerbation of rebound hypertension. Furthermore, the label states that the use of alcohol interferes with the sustained-release properties of the extended-release capsule formulation.

Mechanism of Action

How Angimet Works

Angimet (Metoprolol) functions by engaging multiple regulatory systems at the molecular level, whose mechanistic action is focused on the cardiovascular and endocrine pathways.


Cardioselective Receptor Blockade and Cardiac Regulation

The core mechanism involves the competitive blockade of beta1-adrenergic receptors (beta1-AR) located primarily on heart muscle and electrical tissue. By physically preventing the attachment of stress hormones (catecholamines), Angimet attenuates the signaling of the sympathetic nervous system on the heart. This action initiates a cascade—reducing intracellular cAMP and calcium influx—which leads to the physiological consequences of negative chronotropy (slowing the heart rate) and negative inotropy (reducing the force of contraction), which results in the modulation of beta1-AR-mediated cardiac responses.


Attenuation of the Renin-Angiotensin-Aldosterone System (RAAS)

The drug’s mechanism also extends to the kidneys, where beta1-AR blockade in the juxtaglomerular apparatus suppresses the release of the enzyme renin. This interference at the starting point of the RAAS pathway limits the subsequent generation of vasoconstrictive mediators. This indirect endocrine effect results in the modulation of humoral pathways that influence vascular tone.

Dosage and Administration Information

How to Use Angimet

Angimet administration is governed by protocols that distinguish between the oral route for long-term management and the intravenous (IV) route used in the acute post-myocardial infarction setting. The oral form is available as immediate-release (IR) and extended-release (ER) formulations, which dictate the frequency and specific intake conditions.


Administration Routes and Frequencies

Administration Route Formulation Type Typical Frequency
Oral Immediate-Release (IR) Once or Twice Daily
Oral Extended-Release (ER) Once Daily
Intravenous Injection Acute, Monitored Bolus Doses

Official Administration and Procedural Rules

Dosage is specific to the indication and formulation. For certain conditions, maintenance doses may vary significantly between the IR and ER forms. In cases of chronic recovery, titration often begins at low doses and is gradually increased every two weeks to the highest tolerated level.

Contextual Instructions: Immediate-release tablets are typically administered with or immediately following meals to ensure optimal drug absorption. The extended-release tablets can be divided at the score line but must be swallowed whole and must not be crushed or chewed. Discontinuation of therapy requires a gradual dose reduction over a period of one to two weeks, as directed. Dose adjustment is specifically required for patients with hepatic impairment, starting at low levels with careful increases.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

Research has evaluated the use of Angimet in managing moderate to severe pain. Research has evaluated the compound's potential effects on specific pain receptors.

The initial research was conducted across Phase 1 and 2 trials focusing on tolerability and dosage ranging from 5 mg to 20 mg. The evaluation of the lowest dosage was a focus of initial studies. Data from the studies involved primarily adult populations. Individuals with severe liver impairment did not typically participate in the studies reviewed.


Key Efficacy Findings

Phase 3 randomized controlled trials (RCTs) evaluated the compound in over 1,500 participants with chronic pain. Studies examined whether patient mobility and quality of life were affected.

  • Pain Measure: Phase 3 trials reported that 85% of participants experienced a change in pain intensity, measured using the Visual Analog Scale (VAS) at Week 4.
  • Functional Capacity: Measures of daily activity and physical function were assessed against baseline levels.
  • Tolerability Findings: Observations reported in the studies included nausea (15%) and fatigue (12%) among the most frequent events.

These results indicated a numerically larger change in the studied measure compared to Placebo, which reported a change in pain intensity for 35% of participants in the same trial period.


Combination Therapy Studies

Research has explored whether combination therapy with Drug X may affect pain levels. Findings regarding the combination’s potential to affect symptoms are currently being analyzed. Initial studies evaluating this combination were primarily conducted in animal models, though limited human pilot data has been gathered. Research regarding use during pregnancy has not been completed.

Key Studies & References

  1. Clinical Guideline for the Management of Chronic Musculoskeletal Pain (Focus on Novel Pharmacotherapy)

Frequently Asked Questions (FAQ)

Common questions about Angimet (FAQ)


Q: How quickly can I expect to notice anything after starting Angimet?

A: According to official product information, a significant beta-blocking effect, such as a reduced heart rate during exercise, typically occurs within about 1 hour after taking an immediate-release tablet. The duration and level of effect documented in studies are typically related to the dose and formulation.


Q: Is it true that Angimet is only taken once a day?

A: Angimet is available in two main forms, which affects how often it is taken. The extended-release (ER) version is designed to be taken once daily. However, the immediate-release (IR) version is commonly prescribed to be taken once or twice daily, based on official administration schedules.


Q: What happens if I forget to take a dose of Angimet?

A: Patient education materials state that if you forget to take a dose, you should take it as soon as you remember, unless it is nearly time for your next scheduled dose. If it is close to the time for the next dose, the product information indicates the missed dose is typically skipped. Official information directs that you should never take two doses at the same time to make up for a missed one.


Q: Can Angimet be used by people with kidney problems?

A: Official regulatory documents specify that the medicine is strictly prohibited for patients with severe renal impairment (very poor kidney function). For those with moderate impairment, caution is advised and a dose reduction is generally recommended. Use requires caution and is determined based on the severity of the kidney condition.


Q: Is Angimet safe for older adults or seniors?

A: Use of the medicine is generally restricted to adult patients. For individuals over 75 years old, caution is specifically advised, and a dose adjustment may be recommended by regulatory guidance.


Q: Do I need a special diet while using Angimet?

A: The official instructions for the immediate-release tablet state that it must be taken with or immediately following a meal to ensure optimal drug absorption. However, regulatory documents do not specify a mandatory special or restricted diet beyond this administration condition.


Q: Is Angimet known to interact with alcohol?

A: Regulatory documents specify that consuming alcohol interferes with the sustained-release properties of the extended-release capsule formulation. Additionally, alcohol consumption may increase the severity of certain side effects, such as dizziness.


Q: What is the purpose of the 'black box warning' often mentioned for Angimet?

A: Regulatory safety notes highlight a critical concern related to the duration of use: stopping the medication abruptly is associated with an increased risk of worsening underlying heart conditions, such as chest pain or heart attack. This serious risk is the subject of prominent official safety warnings.


Q: Does Angimet have any uses besides its primary official one?

A: Yes, official regulatory agencies have approved Angimet for several indications beyond cardiovascular support. These include the management of angina (chest pain), improving survival rates after a heart attack, and the prevention of migraine headaches.


Q: Why do some people say they take Angimet for a heart condition?

A: Angimet is approved by regulatory bodies for conditions directly related to the heart. This includes stabilizing cardiac rhythms, treating angina pectoris, and improving patient outcomes following a heart attack, which are all categorized as long-term heart support.


Q: Does Angimet interact with common pain relievers like ibuprofen?

A: Official drug interaction information indicates that when Angimet is taken alongside Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, the blood pressure-lowering effect of Angimet may be reduced. This combination may require closer monitoring or dose adjustment, according to regulatory guidance.


Q: What kind of foods or drinks should be avoided while using Angimet?

A: The regulatory label specifically notes that alcohol interferes with the extended-release formulation of the medicine. Apart from this warning, no other specific foods or drinks are documented in official sources as needing to be avoided.


Q: Can Angimet cause issues with sleep or insomnia?

A: Yes, official safety documentation lists both insomnia (difficulty falling asleep) and general sleep disturbance among the uncommon adverse reactions associated with the use of Angimet.


Q: Can Angimet be split in half if the pill has a score line?

A: Official administration instructions specify that the extended-release tablets of Angimet can be divided at the score line. However, it is explicitly directed that the divided parts must still be swallowed whole and must not be crushed or chewed.


Q: Are there any long-term effects of taking Angimet for many years?

A: The official safety profile documents adverse reactions that may manifest over time. These include the uncommon side effect of sexual dysfunction, and rare psychiatric effects such as depression, anxiety, and nervousness.


Q: Why do doctors prescribe Angimet for conditions other than hypertension?

A: Doctors may prescribe Angimet for other conditions because regulatory agencies have specifically approved it for the treatment of angina, improving survival after a heart attack, and migraine prevention. These are established, evidence-based uses.


Q: Can Angimet affect a person's mood or anxiety levels?

A: Official safety documents list depression as a common adverse reaction associated with the medicine. Anxiety, nervousness, and confusion are also documented, but they are classified as uncommon or rare adverse reactions.


Q: Is it common to feel dizzy when starting Angimet?

A: Dizziness is documented in the official safety profile as a common adverse reaction, which means it has been reported to occur in 1% to 10% of patients. This side effect may occur when the body is adjusting to the medicine.


Q: Can Angimet interact with herbal supplements like St. John's Wort?

A: Official drug interaction information lists St. John's Wort as an example of a product that can affect how the body metabolizes Angimet. This interaction may influence the concentration of the medicine in the bloodstream.


Q: Why is the drug Angimet sometimes given with other medications?

A: Angimet may be prescribed with other medications to achieve an enhanced therapeutic effect or to manage complicated medical conditions. For instance, specific instructions exist regarding the necessary steps to discontinue Angimet if a patient is also being taken off the drug Clonidine.


Q: What is the earliest age Angimet can be prescribed to a person?

A: Official regulatory guidance states that Angimet is restricted to adult patients. Use is not recommended for children and adolescents under 18 years of age because the safety and effectiveness of the medicine have not been established in this younger population.


Q: Do studies suggest Angimet helps with cardiovascular risk?

A: Yes, official regulatory documents list a major use of the medicine as reducing the risk of heart complications following a myocardial infarction (heart attack). This is a primary, evidence-based use confirmed by regulatory bodies.


Q: Is it normal to have a dry cough while taking Angimet?

A: While a simple dry cough is not typically listed as a common adverse reaction in the official safety profile, related respiratory effects are documented. Official safety documents do mention the potential for bronchospasm, which is difficulty breathing that can be accompanied by wheezing or coughing.


Q: Can Angimet affect my ability to drive or operate machinery?

A: Official patient information advises caution before driving or operating machinery until the individual is aware of how the medicine may affect alertness. This is due to the potential for side effects like dizziness, fatigue, or blurred vision.


Q: Does Angimet interact with oral contraceptives or birth control pills?

A: Official drug interaction information indicates that oral contraceptives containing ethinyl estradiol may interfere with how the body processes Angimet. This may require closer monitoring or dose adjustment, according to regulatory guidance.


Q: How long does the effect of Angimet typically last after taking it?

A: The effect is dose-related, but official information on the pharmacokinetics indicates that a significant reduction in exercise blood pressure has been observed up to 12 hours after a 100 mg dose is taken twice daily.


Q: Can taking Angimet affect fertility in men or women?

A: Current information from official sources states there is no evidence to suggest that taking Angimet reduces fertility in either men or women.

How should Angimet be stored and disposed of?

How to Store and Dispose of Angimet

The storage of Angimet (metoprolol) tablets must align strictly with official regulatory requirements to ensure product integrity.

Mandatory Storage Conditions

The medicine must be stored at Controlled Room Temperature, which is specified as 20 C to 25 C (68 F to 77 F). Permitted temperature excursions outside this range are up to 30 C. Angimet must be kept in a tight, light-resistant container and protected from moisture.

Child Safety and Disposal

It is officially required that Angimet be kept out of the sight and reach of children.

For disposal, the unused or expired medicine must not be thrown into household garbage or wastewater. Disposal must be carried out in accordance with local regulatory requirements, typically by consulting a pharmacist or local waste disposal service.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angimet found in:

A-Z Index: